Журнал клинических случаев

Research Progress of Novel Coronavirus Pneumonia Vaccine

Abstract

Song Peng

Since novel coronavirus pneumonia (novel coronavirus pneumonia) novel coronavirus outbreak, countries around the world have accelerated the development of a new coronavirus pneumonia vaccine (new crown vaccine). As of December 2020, 60 candidate new coronal vaccines have been approved for clinical trials, among which 7 vaccines (3 inactivated vaccines, 2 mRNA nucleic acid vaccines, and 2 vector vaccines) have been approved for emergency use or conditional marketing. In this paper, the development progress, advantages, and disadvantages of six new coronal vaccines including inactivated vaccine, nucleic acid vaccine, vector vaccine, protein subunit vaccine, live attenuated vaccine and virus-like particle vaccine was reviewed. The results of the novel coronavirus pneumonia in phase III clinical trials show that the new vaccine has good safety and immunogenicity. The approved vaccine has been proved to have good protective efficacy. However, attention should be paid to the adverse reactions of the vaccine and the long-term protective effect.